Method for pulmonary and oral delivery of pharmaceuticals
US6616914B2 · kind B2 · utility
21Cited by
5References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2001 |
| Grant date | Sep 9, 2003 |
| Priority date | — |
| Expiry date | Jul 17, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In a powder formulation for use in a dry powder inhaler, a pharmaceutical acts as its own carrier, so that use of lactose or other excipients are not needed. The dry powder formulation has a single active pharmaceutical compound having two major populations in particle size distribution: microfine particles of the active pharmaceutical, of 1-10 microns in diameter, and larger carrier particles, also of the active pharmaceutical compound. The carrier particles provide a long acting, delayed onset, and optionally therapeutic effect via the GI tract, while the microfine particles provide a fast onset effect via the lung.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.